Drug Trial Radar · NCT07722780
Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial adopted a multicenter, randomized, double-blind, placebo-controlled design and consisted of two parts: Part Ⅰ and Part Ⅱ.
Conditions
- Premature Ejaculation
Interventions
VV913 2mg CapsulesDrug
VV913 2mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse
VV913 5mg CapsulesDrug
VV913 5mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse
VV913 10mg CapsulesDrug
VV913 10mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse
PlaceboDrug
VV913 Placebo Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean intravaginal ejaculatory latency time (IELT) over the treatment periodTime frame: Part I: Week 4; Part II: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.